Current Reports (8-K / 6-K)

The company sold 646,159.5315 common shares in a private offering on April 1, 2026.

Total consideration was $16,196,500 plus applicable upfront selling commissions and dealer manager fees.

Class F-I common shares accounted for 379,750.6198 shares sold for $9,526,500.

Class F-S common shares accounted for 266,408.9117 shares sold for $6,697,125.

The offering was exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.

The sale was part of the company's continuous private offering program.

The company executed a 1-for-20 reverse stock split effective April 1, 2026, reducing the number of outstanding shares.

Stockholders approved a reverse stock split ratio range of 1:2 to 1:30 at the annual meeting on March 25, 2026, with the Board selecting the specific 1:20 ratio.

The number of shares available under the 2011 Plan, 2021 Plan, and 2021 ESPP, and outstanding awards under these plans, were proportionately decreased and adjusted.

Outstanding warrants to purchase common stock were proportionately adjusted in accordance with their agreements, affecting shares purchasable and exercise prices.

No fractional shares were issued; fractional share entitlements were rounded down to the nearest whole share, with cash payments in lieu.

The authorized shares of common stock remained at 500 million shares, and trading on the NYSE continued under the symbol 'BARK' on a split-adjusted basis.

Nelnet secured a new $435 million unsecured line of credit with a five-year term maturing March 31, 2031.

The new credit facility replaces a $495 million line that was terminated with no outstanding balance.

Interest rates on borrowings will vary based on market conditions, the company's credit rating, and other factors.

The agreement includes financial covenants requiring minimum consolidated net worth and adjusted EBITDA to recourse indebtedness ratios.

Violation of covenants could trigger a default, potentially restricting access to the $435 million available credit.

Certain company subsidiaries guarantee the obligations under the new credit agreement.

Caroline Sullivan appointed Senior Vice President, Chief Accounting Officer, and Controller effective April 29, 2026.

Prior roles: VP Procurement and Real Estate at Elevance Health (June 2025-March 2026), SVP Chief Accounting Officer at Moody's (2018-2025).

Initial base salary $525,000; target bonus 75% of base ($393,750).

Equity: $1M RSUs (May 2026), $1M new hire RSUs (May 2026), $1M target PSUs (March 2027).

Signing bonus $300,000; severance includes 1x base + target bonus upon termination without cause.

Entered Non-Competition, Non-Solicitation, and Employee Confidentiality Agreements.

The IPO closed on April 2, 2026, with 10,520,000 shares sold at $20.00 each, generating ~$193.8 million in net proceeds after underwriting discounts and expenses.

Proceeds will fund $39.5 million to acquire B.V. Voting Shares from Baker Hughes and Akastor, and the remainder will be contributed to HMH B.V. to repay $137.1 million in shareholder loans.

Baker Hughes and Akastor each retain 16.3 million shares of Class B common stock and 32.6 million non-voting B.V. shares, with contractual rights to designate up to two directors each.

A Tax Receivable Agreement obligates HMH to pay 85% of future U.S. tax savings arising from basis step-ups, potentially creating substantial long-term liabilities.

The Company adopted the 2026 LTIP, reserving 3.7 million Class A shares for employee and director awards, including RSUs and performance-based incentives.

Two new independent directors—Lance T. Loeffler and Kathleen S. McAllister—were appointed effective April 1, 2026, expanding the Board to seven members.

Gerard A. Champi appointed President of Peoples and Peoples Bank effective April 3, 2026, continuing as CEO.

Thomas P. Tulaney retires as President effective April 3, 2026, after prior announcement.

Peoples Bank entered Consulting Agreement with Tulaney for senior advisory services at $8,000 per month, terminable with 30 days' notice.

Accelerated vesting of 207 restricted shares and 709 RSUs for Tulaney upon retirement; transferred company vehicle.

Elisa Zúñiga Ramirez will not stand for reelection as director at 2026 annual meeting, not due to disagreement.

Boards to reduce directors: Peoples from 15 to 14, Peoples Bank from 17 to 15, effective 2026 annual meeting.

Lead Director William Concannon will retire effective July 16, 2026, after 26 years on the board, with no disagreement cited.

Director Christine Detrick was appointed as the new independent Lead Director, effective July 16, 2026, pending her re-election.

Concannon's retirement is to spend more time with family and other activities, not due to operational disagreements.

Detrick currently chairs the Nominating and Corporate Governance Committee and has served on the board since 2020.

The leadership transition maintains board continuity with an experienced internal director assuming the lead role.

Transaction for sale of B Medical Systems did not close by March 31, 2026 due solely to Thelema's unmet financing condition.

Thelema requires additional time to complete financing arrangements.

Sale and Purchase Agreement remains in effect; no amendments or termination.

Company evaluating potential paths forward while Thelema works on financing.

No assurance Transaction will complete on revised timeline or at all.

Total revenues decreased 17.1% year-over-year to RMB2,525.9 million, driven by a 17.5% decline in on-demand food delivery solutions.

Net loss attributable to Quhuo Limited was RMB150.5 million for 2025, compared to net income of RMB1.6 million in 2024.

Housekeeping and accommodation solutions revenue surged 75.9% to RMB76.0 million, highlighting a new growth area.

General and administrative expenses increased 26.3% to RMB187.8 million, impacted by RMB25.6 million in credit loss provisions.

The Company held cash, cash equivalents and restricted cash of RMB40.0 million against short-term debt of RMB113.4 million as of December 31, 2025.

Management expects business efficiency and profitability improvements to become visible starting in the second quarter of 2026 following restructuring.

Third Amendment to Everli Note executed March 30, 2026, increases principal to up to $3,611,111 to reflect $361,111 original issue discount.

Third Amendment to Sponsor Note issued March 30, 2026, increases principal to up to $3,611,111.

Amendments relate to previously disclosed notes dated August 18, 2025, with prior amendments in September 2025.

Sponsor Note amendment exempt from registration under Section 4(a)(2) of Securities Act.

Exhibits 10.1 and 10.2 filed containing full amendment texts.

Part of ongoing Business Combination with Everli Global Inc. via Merger Agreement.

Third Amendment to Everli Note executed March 30, 2026, increases principal to up to $3,611,111 to reflect $361,111 original issue discount.

Third Amendment to Sponsor Note issued March 30, 2026, increases principal to up to $3,611,111.

Amendments relate to previously disclosed notes dated August 18, 2025, with prior amendments in September 2025.

Sponsor Note amendment exempt from registration under Section 4(a)(2) of Securities Act.

Exhibits 10.1 and 10.2 filed containing full amendment texts.

Part of ongoing Business Combination with Everli Global Inc. via Merger Agreement.

Third Amendment to Everli Note executed March 30, 2026, increases principal to up to $3,611,111 to reflect $361,111 original issue discount.

Third Amendment to Sponsor Note issued March 30, 2026, increases principal to up to $3,611,111.

Amendments relate to previously disclosed notes dated August 18, 2025, with prior amendments in September 2025.

Sponsor Note amendment exempt from registration under Section 4(a)(2) of Securities Act.

Exhibits 10.1 and 10.2 filed containing full amendment texts.

Part of ongoing Business Combination with Everli Global Inc. via Merger Agreement.

Investment management rights for five AIFs—including India Advantage Fund S4 I, S5 I, S5 II, India Real Estate Investment Fund Series 2, and Iven Amplifi Fund—have been transferred to ICICI Prudential AMC effective April 1, 2026.

The transfer follows prior disclosures on May 9, 2025 and March 2, 2026, and was confirmed via email received by ICICI Bank at 4:20 p.m. on April 2, 2026.

ICICI Prudential AMC has executed requisite agreements with ICICI Venture Funds Management Company Limited to assume investment management services for the listed AIFs.

All five AIFs are registered with SEBI, with registration numbers explicitly disclosed in the filing.

The 2026 Annual Meeting is scheduled for June 9, 2026, to be held virtually.

The record date for determining voting eligibility is May 15, 2026.

The deadline for stockholder proposals and director nominations is April 12, 2026.

The company reserves the right to change the meeting or record date.

The previous deadline from the 2025 proxy statement no longer applies due to the meeting date change.

The Board approved the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan on March 31, 2026.

The plan reserves 1,750,000 shares of common stock for issuance to eligible new employees.

Awards under the plan are restricted to new hires as a material inducement to employment under Nasdaq Rule 5635(c)(4).

The plan was adopted without stockholder approval, relying on the Nasdaq listing rule exception.

The company will file the complete plan documents as exhibits to its upcoming Quarterly Report on Form 10-Q.

Elijio V. Serrano retires as SVP and CFO effective March 31, 2026, after announcing intent on October 24, 2025.

Matthew J. Sanderson appointed EVP and CFO effective upon Serrano's retirement; retains certain commercial responsibilities.

Sanderson's base salary increases to $490,000 from $467,500; target incentive to 90% of base from 80%; long-term awards to $925,000 from $750,000.

Sanderson's change of control benefits amended to 2.5x base salary and target bonus.

Serrano's transition agreement provides $125,000 annual salary as advisor through April 2, 2027, with prorated incentives and continued equity vesting.

Serrano receives additional 17,922 restricted stock units vesting April 2, 2027.

Board size increased from ten to twelve directors effective April 1, 2026.

Frances L. Allen appointed as independent director with over 40 years in consumer and food industry leadership.

Felicia D. Thornton appointed as independent director with over 30 years in grocery, retail, and finance expertise.

Both qualify as independent under Nasdaq rules and receive standard non-employee director compensation.

Appointments followed national search to enhance Board expertise in retail operations and strategy.

No family relationships or material transactions with Allen or Thornton disclosed.

The Company amended Warrants from June 2023 and June 2025 offerings to revise beneficial ownership blockers that caused unintended liability classification.

Warrants were previously classified as liabilities, resulting in recorded liabilities of $18.1 million and $25.2 million for the quarters ended September 30, 2025, and December 31, 2025, respectively.

The Company expects the amendment to reduce warrant liability on its financial statements and increase equity value by the corresponding amount.

The amended warrants clarify that stockholders cannot vote to amend or change the Blockers, resolving the ambiguity that drove the liability classification.

The issuance of amended warrants was not registered under the Securities Act, relying on exemptions under Section 3(a)(9) and Section 4(a)(2).

PMGC formed a new wholly owned subsidiary named NorthStrive Defense Tech LLC.

The subsidiary will operate in the defense technology sector, focusing on drone technology and autonomous systems.

The strategy involves identifying, acquiring, and licensing advanced defense technologies through acquisitions, licensing, and partnerships.

PMGC intends to leverage its existing subsidiaries, AGA Precision Systems LLC and Silicon Valley Machining, Inc., to accelerate commercialization.

The Company stated there is no assurance the subsidiary will successfully identify, acquire, license, or commercialize any technologies or generate revenue.

Securitization program aggregate size increased $500 million to $2 billion.

Accordion feature decreased $500 million from $1 billion to $500 million.

Added U.S. subsidiary (Bunge USA Grain, LLC) as seller; German subsidiary removed.

Canadian subsidiary (Bunge Canada Inc.) permitted to join upon conditions.

Removed sustainability provisions and revised applicable margin.

Recourse limited to first loss position based on historical receivables performance.

The Hart-Scott-Rodino (HSR) Act waiting period expired on April 1, 2026, satisfying a key regulatory condition for the merger.

The merger is expected to close in the second quarter of 2026, contingent upon satisfaction or waiver of other customary closing conditions.

Under the Merger Agreement, Merger Sub will merge with and into Coterra, with Coterra surviving as a wholly-owned subsidiary of Devon.

Devon filed an S-4 registration statement (declared effective March 26, 2026), and both companies filed and commenced mailing a joint proxy statement/prospectus on March 30, 2026.

The filing explicitly states this 8-K is not a substitute for the joint proxy statement/prospectus, which contains material information for investors and security holders.

Entered Bridge Facility Credit Agreement with PNC Bank for $150 million senior unsecured term loan on March 27, 2026.

Borrowed full $150 million on closing date.

Interest at Term SOFR + 2.50% or Base Rate + 1.50%, at company's option.

Matures on earliest of 364 days after closing or PNC Mortgage Facility refinancing.

Prepayable without premium or penalty; includes standard covenants and events of default.

PNC Mortgage Facility remains outstanding.

The Fund sold 2,433,500 Class B-1 units for $60.8 million and 29,906 Class B-3 units for $747,660 on March 2, 2026.

All units were sold at $25.00 per unit to third-party investors, including through a feeder vehicle.

The sale was exempt from registration under Section 4(a)(2) and Regulation D of the Securities Act.

Transactional NAV per Unit as of February 28, 2026 ranged from $25.00 for Class B units to $26.71 for Class E units.

The Fund invests alongside WP ACE, which sold interests for approximately $80.1 million on the same date.

Exchange Trading Volume declined to ¥324,962 million in March 2026 from ¥461,342 million in October 2025, reflecting a 29% decrease over six months.

Marketplace Trading Volume fell to ¥18,814 million in March 2026 — the lowest level in the 12-month disclosed series — down 47% from its peak of ¥39,165 million in July 2025.

Customer Assets dropped to ¥728,051 million as of March 31, 2026, a 38% decline from the high of ¥1,239,868 million in July 2025.

Number of Verified Accounts increased steadily to 2,527,772 as of March 31, 2026, up 10% from 2,302,376 in April 2025, indicating continued user acquisition despite declining asset and volume metrics.

All disclosed metrics are preliminary, unaudited, and subject to update; the filing explicitly states they should not be extrapolated for future periods.

Completed acquisition of The Brand House Collective (TBHC) on April 2, 2026, with TBHC surviving as wholly owned subsidiary.

Exchange ratio: 0.1993 shares of BBBY Common Stock per TBHC Common Stock share.

No fractional BBBY shares issued; cash paid at $4.66 per share based on April 1, 2026 closing price.

TBHC options and RSUs converted into BBBY Common Stock per exchange ratio; underwater options cancelled without payment.

Entered Contribution Agreement to contribute $30 million to TBHC for general purposes including debt repayment to Bank of America.

TBHC Merger Agreement filed as Exhibit 2.1.

FY 2025 revenue reached $18.3 million, a 66% increase year-over-year, driven by semiconductor demand and the IC'ALPS acquisition.

Q1 2026 revenue is expected to exceed $4 million, representing over 100% growth compared to Q1 2025.

The company reaffirmed FY 2026 guidance with revenue expected to grow between 50% and 100% year-over-year.

Cash and short-term investments totaled over $525 million as of March 31, 2026, following a $125 million capital raise.

FY 2025 net loss was $34.2 million, including an $11.2 million non-cash share-based compensation charge.

QS7001 certification is progressing, with critical Common Criteria EAL5+ testing passed in March 2026.

FY 2025 revenue reached $18.3 million, a 66% increase year-over-year, driven by semiconductor demand and the IC'ALPS acquisition.

Q1 2026 revenue is expected to exceed $4 million, representing over 100% growth compared to Q1 2025.

The company reaffirmed FY 2026 guidance with revenue expected to grow between 50% and 100% year-over-year.

Cash and short-term investments totaled over $525 million as of March 31, 2026, following a $125 million capital raise.

FY 2025 net loss was $34.2 million, including an $11.2 million non-cash share-based compensation charge.

QS7001 certification is progressing, with critical Common Criteria EAL5+ testing passed in March 2026.

Aparna Bawa is resigning as Chief Operating Officer effective May 8, 2026 — a senior executive role overseeing day-to-day operations.

Her resignation was voluntary and not the result of any disagreement with the Company — indicating no underlying governance or performance conflict.

No successor has been named or disclosed — creating near-term uncertainty regarding operational continuity and strategic execution.

The COO role reports directly to the CEO and historically influences go-to-market, product delivery, and scaling — amplifying the significance of this departure.

Zhanpeng 'Frederick' Jiang was appointed as a Class I Director with a term expiring at the 2028 Annual Meeting.

Mr. Jiang was appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.

The Board determined Mr. Jiang qualifies as an independent director under Nasdaq Listing Rule 5605.

Mr. Jiang received an option to purchase 15,000 shares of common stock vesting over one year.

He will receive annual cash retainers totaling $56,500 for Board and committee service.

Zhanpeng 'Frederick' Jiang was appointed as a Class I Director with a term expiring at the 2028 Annual Meeting.

Mr. Jiang was appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.

The Board determined Mr. Jiang qualifies as an independent director under Nasdaq Listing Rule 5605.

Mr. Jiang received an option to purchase 15,000 shares of common stock vesting over one year.

He will receive annual cash retainers totaling $56,500 for Board and committee service.

The weighted-average number of common shares outstanding for basic EPS was 119,856,418 for Q1 2026.

Diluted EPS calculation included 120,783 incremental shares from share-based compensation.

Forward equity offerings added 398,432 weighted-average incremental shares to diluted share count.

The treasury stock method was used to account for dilution from forward equity offerings prior to settlement.

Total weighted-average number of common shares and OP Units for diluted EPS was 120,723,252.

The weighted-average number of common shares outstanding for basic EPS was 119,856,418 for Q1 2026.

Diluted EPS calculation included 120,783 incremental shares from share-based compensation.

Forward equity offerings added 398,432 weighted-average incremental shares to diluted share count.

The treasury stock method was used to account for dilution from forward equity offerings prior to settlement.

Total weighted-average number of common shares and OP Units for diluted EPS was 120,723,252.

The Borrowers secured a revolving credit facility with an initial commitment of $125 million, scheduled to increase to $250 million on April 28, 2026.

The facility has a scheduled maturity date of March 27, 2031, with a three-year reinvestment period during which the commitment may be increased.

Interest rates are based on benchmark rates plus an applicable margin ranging from 1.50% to 3.27%, depending on collateral type and currency.

The Borrowers' obligations are secured by substantially all of their assets, including portfolio investments.

Ares Sports, Media and Entertainment Opportunities LP provided a full recourse, unconditional guarantee for the Borrowers' obligations under the facility.

The facility contains customary representations, warranties, covenants, servicing procedures, and events of default for similar financing transactions.

Board size increased from five to six members on recommendation of Nominating and Governance Committee.

Fred Halvin elected as new director effective May 1, 2026; initially not on any committees.

Halvin directed over 20 M&A transactions totaling approximately $8 billion at Hormel Foods.

Experience includes acquisitions like Planters, Columbus, Applegate, Skippy, and Muscle Milk.

Chairman and CEO Adam L. Michaels highlighted Halvin’s expertise in acquisitions and strategic growth for Company’s deli solutions vision.

Halvin expressed enthusiasm for Company’s growth in deli prepared foods category.

Stabilis GDS terminated 10-year LNG supply agreement with global marine operator on March 31, 2026.

Agreement covered ~50 million gallons/year, or 40% of Galveston facility's 350,000 gallon-per-day capacity.

Included minimum volume commitments of ~32% of planned capacity.

Termination occurred during third-party financing negotiations; counterparty rejected proposed modifications.

Results in expected delays to FID, project financing, and Galveston facility development timeline.

Company pursuing alternative offtake arrangements with potential customers.

Monthly distribution of $0.08 per share declared for April 2026.

Comprised of $0.04 base dividend and $0.04 supplemental dividend.

Record date: April 15, 2026; payable date: May 1, 2026.

Expected to be paid from taxable net investment income.

Final tax characteristics reported on Form 1099 and periodic SEC filings.

Drew €12.0 million Tranche B under Finance Contract with EIB, expected disbursement late April 2026.

Tranche B matures five years from disbursement with interest payable at maturity.

Issued 1,116,244 Tranche B Warrants to EIB on April 1, 2026, exercisable for ordinary shares at €3.23 strike.

Warrants unregistered under Securities Act, relying on Section 4(a)(2) exemption.

Finance Contract originally entered October 17, 2025, for up to €36.0 million in three tranches.

Monthly distribution declared at $0.1025 per share for April 2026.

Record date is April 15, 2026; payment date is May 1, 2026.

Distribution expected to be paid from taxable net investment income.

Operates as a regulated investment company (RIC) generating qualified interest income.

Specific tax characteristics available on www.pennantpark.com.

The company filed a certificate of merger with the Delaware Secretary of State on April 2, 2026.

The merger will become effective on April 6, 2026, at 12:01 a.m. Eastern Time.

At the effective time, BA Merger Sub, Inc. will merge with and into BioAtla, with BioAtla as the surviving corporation.

Every 50 shares of BioAtla common stock will be converted into one share of the surviving corporation.

The merger implements a previously announced agreement and plan of merger adopted by the board on January 30, 2026.

Total AUM reached $25,911 million as of March 31, 2026.

Proprietary Funds represent the largest vehicle at $16,668 million.

Separately managed accounts total $4,169 million.

Large Cap strategy dominates with $10,745 million.

Short Duration Securitized Bond strategy at $5,340 million.

Core Fixed Income strategy totals $3,826 million.

Datasea Inc. received a Nasdaq staff determination notice on March 27, 2026, for non-compliance with the $1 minimum bid price rule.

The notice has no immediate effect on listing, but the company has a 180-day compliance period ending September 23, 2026, to regain compliance.

To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least ten consecutive business days before the compliance date.

If compliance is not regained by September 23, 2026, the company may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of its intent to cure.

The company intends to monitor its stock price and consider available options to regain compliance with Nasdaq listing rules.

CFO Danny Leung appointed Interim CEO effective 2 April 2026, maintaining his CFO responsibilities during the transition.

Former CEO Rohith Murthy concluded his tenure but continues to serve as a Director on the Board.

The Board has initiated a comprehensive search for a permanent Chief Executive Officer.

Chairman Kenneth Chan cited the need to evolve the leadership team to better serve shareholders as the rationale for the transition.

CFO Danny Leung appointed Interim CEO effective 2 April 2026, maintaining his CFO responsibilities during the transition.

Former CEO Rohith Murthy concluded his tenure but continues to serve as a Director on the Board.

The Board has initiated a comprehensive search for a permanent Chief Executive Officer.

Chairman Kenneth Chan cited the need to evolve the leadership team to better serve shareholders as the rationale for the transition.

The company closed a best-efforts public offering of common stock, pre-funded warrants, and accompanying warrants, raising approximately $2.5 million in net proceeds.

The offering included 1,028,788 shares of common stock at $1.32 per share and 1,243,940 pre-funded warrants at $1.31999 each, with accompanying warrants to purchase up to 2,272,728 additional shares.

Warrants issued to investors and the placement agent are not exercisable until stockholder approval is obtained, and if exercised in full for cash, could provide an additional $3.0 million in gross proceeds.

The company agreed to a 30-day lock-up on issuing new securities post-closing and its executives and directors entered into a 30-day lock-up agreement on selling existing securities.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee, a 1.0% management fee, $100,000 in legal fee reimbursement, and warrants to purchase 159,091 shares.

Nasdaq notified Evogene of non-compliance with Rule 5550(a)(2) due to a sustained sub-$1.00 closing bid price — a formal listing deficiency requiring remediation.

The Company has until September 28, 2026 (180 calendar days from April 2, 2026) to regain compliance; failure may lead to delisting unless eligible for a second compliance period.

Compliance can be achieved solely by maintaining a $1.00+ closing bid price for ten consecutive business days — no other metrics or filings are required for initial cure.

Evogene stated it may consider a reverse stock split among other alternatives, but no board action or shareholder approval has been announced or taken.

Board size increased from 8 to 10 directors per amended bylaws — reflects governance scaling ahead of strategic growth.

Jon Girod and Kourosh Zamanizadeh appointed effective March 30, 2026 — both bring regional expertise in real estate development and AI-driven technology.

Appointments made without committee assignments — limits immediate operational influence but preserves flexibility for future role alignment.

No family relationships or SEC-reportable related-party transactions disclosed — supports independence and regulatory compliance.

David Gill appointed Non-Executive Director effective May 11, 2026, as part of Board expansion and succession planning.

Mr. Gill expected to succeed Dr. Mark Nelson as Chair; Nelson remains as NED.

Genevieve Ryan resigns as Company Secretary effective April 2, 2026.

Shomalin Naidoo appointed interim Company Secretary effective April 2, 2026, responsible for ASX communications.

Gill brings 35+ years experience in biopharma finance, U.S. capital markets, and public company leadership.

David Gill appointed Non-Executive Director effective May 11, 2026, as part of Board expansion and succession planning.

Mr. Gill expected to succeed Dr. Mark Nelson as Chair; Nelson remains as NED.

Genevieve Ryan resigns as Company Secretary effective April 2, 2026.

Shomalin Naidoo appointed interim Company Secretary effective April 2, 2026, responsible for ASX communications.

Gill brings 35+ years experience in biopharma finance, U.S. capital markets, and public company leadership.

Julia Rueb appointed as principal accounting officer effective April 1, 2026.

Alan Fuhrman succeeded as principal accounting officer but continues as principal financial officer.

Rueb has served as Vice President, Finance since January 2024 with prior accounting roles at SOAProjects and Ernst & Young.

Rueb holds a Master's in Accounting from University of San Diego and is a Certified Public Accountant.

No family relationships exist between Rueb and the company's directors or executive officers.